Margaret E Macy
Overview
Explore the profile of Margaret E Macy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park J, Villablanca J, Hero B, Kushner B, Wheatley K, Beiske K, et al.
Cancer
. 2022 Sep;
128(21):3775-3783.
PMID: 36101004
Background: International standardized criteria for eligibility, evaluable disease sites, and disease response assessment in patients with refractory, progressive, or relapsed high-risk neuroblastoma enrolled in early-phase clinical trials are lacking. Methods:...
12.
Church A, Corson L, Kao P, Imamovic-Tuco A, Reidy D, Doan D, et al.
Nat Med
. 2022 Jun;
28(8):1581-1589.
PMID: 35739269
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective observational cohort study at...
13.
Dubois S, Macy M, Henderson T
Am Soc Clin Oncol Educ Book
. 2022 May;
42:1-13.
PMID: 35522915
Approximately half of the patients diagnosed with neuroblastoma are classified as having high-risk disease. This group continues to have inadequate cure rates despite multiagent chemotherapy, surgery, high-dose chemotherapy with autologous...
14.
Desai A, Robinson G, Gauvain K, Basu E, Macy M, Maese L, et al.
Neuro Oncol
. 2022 Apr;
24(10):1776-1789.
PMID: 35395680
Background: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1...
15.
Loeb D, Lee J, Morgenstern D, Samson Y, Uyttebroeck A, Lyu C, et al.
Cancer Immunol Immunother
. 2022 Mar;
71(10):2485-2495.
PMID: 35262780
Background: We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in paediatric patients with refractory/relapsed solid tumours. Methods: In phase 1, patients aged < 18 years...
16.
Schienda J, Church A, Corson L, Decker B, Clinton C, Manning D, et al.
JCO Precis Oncol
. 2021 Dec;
5.
PMID: 34964003
Purpose: Molecular tumor profiling is becoming a routine part of clinical cancer care, typically involving tumor-only panel testing without matched germline. We hypothesized that integrated germline sequencing could improve clinical...
17.
Laetsch T, Dubois S, Glade Bender J, Macy M, Moreno L
Cancer Discov
. 2020 Dec;
11(3):545-559.
PMID: 33277309
The use of targeted small-molecule therapeutics and immunotherapeutics has been limited to date in pediatric oncology. Recently, the number of pediatric approvals has risen, and regulatory initiatives in the United...
18.
Rossoff J, Huynh V, Rau R, Macy M, Sulis M, Schultz K, et al.
Br J Haematol
. 2020 Jan;
189(2):363-368.
PMID: 31975387
Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. Among paediatric patients with chronic myeloid leukaemia (n = 9) or acute...
19.
Geoerger B, Kang H, Yalon-Oren M, Marshall L, Vezina C, Pappo A, et al.
Lancet Oncol
. 2019 Dec;
21(1):121-133.
PMID: 31812554
Background: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients. We aimed to establish the recommended...
20.
Dahl N, Liu A, Foreman N, Widener M, Fenton L, Macy M
Childs Nerv Syst
. 2019 Aug;
35(11):2043-2046.
PMID: 31367784
Purpose: Radiation-induced injury is a well-described toxicity in children receiving radiation therapy for tumors of the central nervous system. Standard therapy has historically consisted primarily of high-dose corticosteroids, which carry...